Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NR2C2 | P49116 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 6/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071927 | 0.94 | KDR (0.52) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072151 | 0.85 | RAF1 (0.44) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072414 | 0.84 | KDR (0.52) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072249 | 0.82 | HRH3 (0.48) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072647 | 0.82 | RAF1 (0.54) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072145 | 0.81 | MET (0.47) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072111 | 0.81 | KDR (0.53) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072163 | 0.80 | KDR (0.47) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072190 | 0.80 | HTT (0.46) | KDRNFKB1NR2C2NFKB2RELA | |
| SCHEMBL6072418 | 0.79 | KDR (0.47) | KDRMAPK14BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | ADAMS JERRY L | 2006-10-26 | — | — | US | disclosed |
| EP-1581514-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004043379-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241149-A1 | Chemical compounds | CHKB, MAP3K20, MAP3K6 | KDR 2025/4885NFKB1 858/4885NR2C2 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.